UNSPSC 51451703: Pyrathiazine

This classification denotes a histamine-1 receptor antagonist with the molecular formula C18H20N2S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X0SMC42Q5O, chemically known as N-(beta-Pyrrolidinoethyl)phenothiazine but generally known as pyrathiazine, which bears US NIH Compound Identifier 10646. SMILES: C1CCN(C1)CCN2C3=CC=CC=C3SC4=CC=CC=C42.Cl.

UNSPSC 51451703 Pyrathiazine is a Commodity-tier code that covers pharmaceutical and medical supply procurement by state and local health agencies, though recent opportunities under this code's designation show limited direct correlation to pyrathiazine specifically. State and local governments are buying pharmaceutical products—including naloxone, generic multi-source pharmaceuticals, and over-the-counter products—through health departments, purchasing alliances, and emergency services divisions. The work involves competitive bidding for pharmaceutical supply contracts, with vendors required to meet FDA compliance, cGMP certification, Drug Supply Chain Security Act (DSCSA) adherence, drug-free workplace requirements, and E-Verify compliance. Issuing bodies include state health departments, county health agencies, municipal fire rescue divisions, and cooperative purchasing alliances spanning multiple jurisdictions; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) and state health commissions represent the largest buyers in recent activity.

Recent opportunities span Florida, Texas, Minnesota, and multiple participating states. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 drug deactivation systems annually for quarterly delivery, with a July 26, 2023 response deadline and a two-year initial term plus one-year renewal option. The City of Tampa's Purchasing Department released IFB 26P00145 in March 2026 for 169 line items of medical and first aid supplies for the Tampa Fire Department Rescue Division, with an estimated contract value of $700,000 and a small local business enterprise (SLBE) 5% bid discount not to exceed $10,000. The Minnesota Department of Administration issued RFP S1070000015802 in January 2026 through MMCAP for generic multi-source pharmaceuticals and OTC products across participating state and local facilities, with proposals due March 26, 2026, and awarded products effective July 1, 2026. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, with a response deadline of April 3, 2026.